Lasolvan® in treatment of acute and chronic respiratory tract infections
Inflammatory diseases of respiratory tract hold one of the leading places in the structure of general morbidity. Coughing as a defense reaction to inflammatory process accompanies many illnesses. Dry irritating cough occurs upon disease progression. Nowadays, in pediatric practice dry cough is broadly treated by using a new-generation mucolytic drug Lasolvan® (ambroxol) which is an active metabolite of bromhexine.